QTc Prolongation with Antipsychotics
- 1 May 2014
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Psychiatric Practice
- Vol. 20 (3), 196-206
- https://doi.org/10.1097/01.pra.0000450319.21859.6d
Abstract
Whether or not QTc interval should be routinely monitored in patients receiving antipsychotics is a controversial issue, given logistic and fiscal dilemmas. There is a link between antipsychotic medications and prolongation of QTc interval, which is associated with an increased risk of torsade de pointes (TdP). Our goal is to provide clinically practical guidelines for monitoring QTc intervals in patients being treated with antipsychotics. We provide an overview of the pathophysiology of the QT interval, its relationship to TdP, and a discussion of the QT prolonging effects of antipsychotics. A literature search for articles relevant to the QTc prolonging effects of antipsychotics and TdP was conducted utilizing the databases PubMed and Embase with various combinations of search words. The overall risk of TdP and sudden death associated with antipsychotics has been observed to be low. Medications, genetics, gender, cardiovascular status, pathological conditions, and electrolyte disturbances have been found to be related to prolongation of the QTc interval. We conclude that, while electrocardiogram (ECG) monitoring is useful when administering antipsychotic medications in the presence of co-existing risk factors, it is not mandatory to perform ECG monitoring as a prerequisite in the absence of cardiac risk factors. An ECG should be performed if the initial evaluation suggests increased cardiac risk or if the antipsychotic to be prescribed has been established to have an increased risk of TdP and sudden death.Keywords
This publication has 27 references indexed in Scilit:
- New atypical antipsychotics for schizophrenia: iloperidoneDrug Design, Development and Therapy, 2010
- Sudden death in patients receiving drugs tending to prolong the QT intervalBritish Journal of Clinical Pharmacology, 2009
- Electrocardiographic monitoring for QT prolongation in patients treated with ziprasidone-A claims database approachPharmacoepidemiology and Drug Safety, 2009
- Sudden cardiac death and antipsychotics Part 2: Monitoring and preventionAdvances in Psychiatric Treatment, 2006
- Modeling and Interpreting QTc Prolongation in Clinical Pharmacology StudiesDrug Information Journal, 2005
- Ziprasidone in the Management of SchizophreniaCNS Drugs, 2003
- Aripiprazole: profile on efficacy and safetyExpert Opinion on Pharmacotherapy, 2002
- Electrocardiograms, high-dose antipsychotic treatment and College guidelinesPsychiatric Bulletin, 1996
- The dilemma of the prolonged QT interval in early drug studiesBritish Journal of Clinical Pharmacology, 1996
- Measurement of the QT interval and the risk associated with QTc interval prolongation: A reviewThe American Journal of Cardiology, 1993